Fong L - Search Results

1

Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.

Cha E, Fong L. Cha E, et al. Among authors: fong l. Oncoimmunology. 2018 Mar 13;7(4):e956016. doi: 10.4161/21624011.2014.956016. eCollection 2018. Oncoimmunology. 2018. PMID: 29632706 Free PMC article.

2

Therapeutic vaccines for prostate cancer.

Cha E, Fong L. Cha E, et al. Among authors: fong l. Curr Opin Mol Ther. 2010 Feb;12(1):77-85. Curr Opin Mol Ther. 2010. PMID: 20140819 Review.

3

Immunotherapy for prostate cancer: biology and therapeutic approaches.

Cha E, Fong L. Cha E, et al. Among authors: fong l. J Clin Oncol. 2011 Sep 20;29(27):3677-85. doi: 10.1200/JCO.2010.34.5025. Epub 2011 Aug 8. J Clin Oncol. 2011. PMID: 21825260 Free PMC article. Review.

4

Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Kwek SS, Cha E, Fong L. Kwek SS, et al. Among authors: fong l. Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi: 10.1038/nrc3223. Nat Rev Cancer. 2012. PMID: 22378189 Free PMC article. Review.

5

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Cha E, et al. Among authors: fong l. Sci Transl Med. 2014 May 28;6(238):238ra70. doi: 10.1126/scitranslmed.3008211. Sci Transl Med. 2014. PMID: 24871131 Free PMC article.

6

GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.

Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. Kwek SS, et al. Among authors: fong l. Oncoimmunology. 2015 Oct 29;5(4):e1101204. doi: 10.1080/2162402X.2015.1101204. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141383 Free PMC article.

7

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. Small EJ, et al. Among authors: fong l. Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318. Clin Cancer Res. 2007. PMID: 17363537 Clinical Trial.

8

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.

Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Kwek SS, et al. Among authors: fong l. J Immunol. 2012 Oct 1;189(7):3759-66. doi: 10.4049/jimmunol.1201529. Epub 2012 Sep 5. J Immunol. 2012. PMID: 22956585 Free PMC article. Clinical Trial.

9

Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Cheng ML, Fong L. Cheng ML, et al. Among authors: fong l. Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z. Curr Treat Options Oncol. 2014. PMID: 24402184 Free PMC article. Review.

10

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.

Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Kwek SS, et al. Among authors: fong l. Cancer Immunol Res. 2015 Sep;3(9):1008-16. doi: 10.1158/2326-6066.CIR-14-0227. Epub 2015 May 12. Cancer Immunol Res. 2015. PMID: 25968455 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

682 results

Search Page

Filters